U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT07506512) titled 'Optimal Time Interval Between Mifepristone and Misoprostol Administration for Early Pregnancy Loss' on March 26.
Brief Summary: A prospective cohort study to explore the optimal time interval between mifepristone and misoprostol administration for medical management of early pregnancy loss. Participants will be followed to assess treatment success, satisfaction, and side effects.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Early Pregnancy Loss
Intervention:
DRUG: 200mg mifepristone and 800mg misoprostol
Participants will take 200mg of mifepristone by mouth and will be instructed to administer misoprosto...